山东大学学报 (医学版) ›› 2024, Vol. 62 ›› Issue (1): 115-119.doi: 10.6040/j.issn.1671-7554.0.2023.0955
• 病例报道 • 上一篇
潘庆鑫1,2,3,张越1,2,3,刘松涛4,陈海燕1,2,3,王哲1,2,3
中图分类号:
| [1] Tan A, Ralston SH. Pagets disease of bone[J]. QJM, 2014, 107(11): 865-869. [2] Patil AK, Muthusamy K, Aaron S, et al. A case of Erdheim Chester disease with central nervous system involvement[J]. Ann Indian Acad Neurol, 2015, 18(3): 338-341. [3] Maatallah K, Ben Nessib D, Labbène E, et al. Pagets disease of bone in patients under 40 years: two case reports and review of the literature[J]. Sultan Qaboos Univ Med J, 2021, 21(1): e127-e131. [4] Wani S, Daroszewska A, Salter DM, et al. The Pagets disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption[J]. Dis Model Mech, 2022, 15(4): dmm049318. [5] Gennari L, Rendina D, Merlotti D, et al. Update on the pathogenesis and genetics of Pagets disease of bone[J]. Front Cell Dev Biol, 2022, 10: 932065. doi:10.3389/fcell.2022.932065. [6] Cundy T. Pagets disease of bone[J]. Metabolism, 2018, 80: 5-14. doi: 10.1016/j.metabol.2017.06.010. [7] Cundy T, Maslowski K, Grey A, et al. Durability of response to zoledronate treatment and competing mortality in Pagets disease of bone[J]. J Bone Miner Res, 2017, 32(4): 753-756. [8] Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-chester disease: a comprehensive review of the literature[J]. Orphanet J Rare Dis, 2013, 8: 137-149. doi: 10.1186/1750-1172-8-137. [9] Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-chester disease[J]. Blood, 2020, 135(16): 1311-1318. [10] Papo M, Emile JF, Maciel TT, et al. Erdheim-chester disease: a concise review[J]. Curr Rheumatol Rep, 2019, 21(12): 66. [11] Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era[J]. Blood, 2020, 135(22): 1929-1945. [12] Pan ZG, Kleinschmidt-DeMasters BK. CNS erdheim-chester disease: a challenge to diagnose[J]. J Neuropathol Exp Neurol, 2017, 76(12): 986-996. [13] Cives M, Simone V, Rizzo FM, et al. Erdheim-Chester disease: a systematic review[J]. Crit Rev Oncol Hematol, 2015, 95(1): 1-11. [14] Shekhar S, Irizarry-Caro JA, Sinaii N, et al. Pituitary imaging abnormalities and related endocrine disorders in erdheim-chester disease[J]. Cancers(Basel), 2021, 13(16): 4126. [15] Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages[J]. Blood, 2016, 127(22): 2672-2681. [16] Nordmann TM, Juengling FD, Recher M, et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations[J]. Blood, 2017, 129(7): 879-882. |
| [1] | 漆苏, 陈蕊, 漆学良. 以突眼、眼球胀痛为主要表现的GQ1b抗体阳性Miller-Fisher综合征1例[J]. 山东大学学报（医学版）, 2015, 53(5): 95-96. |
| [2] | 孙亚方1，王银昌2，王来城3，焦玉莲3，崔彬3，夏羽3，卢冰如3，赵跃然1,3. 一个Paget骨病家系SQSTM1及TNFRSF11A基因突变分析[J]. 山东大学学报(医学版), 2012, 50(12): 107-113. |
|
||
